Dr. Reddy's (RDY) Q2 2027 Earnings Call Transcript

Dr. Reddy’s Q2 FY27 revenue fell 1.5% year over year to $905 million, while EBITDA margin was 20.6%; gross margin declined 254 basis points to 52.1%. North American revenue dropped 29% to $264 million, mainly reflecting lower lenalidomide sales, while emerging-markets revenue rose 84% to ₹2,059 crore and India revenue grew 17.8% sequentially. Management cited Middle East-related supply disruptions and higher freight costs, estimating about 100 basis points of EBITDA impact, and said these cost pressures may continue in Q3 and Q4. Semaglutide supply resumption is targeted for November 2026 subject to validation, while abatacept faces a possible FDA Complete Response Letter ahead of its Dec. 22, 2026 goal date.

Analysis

The key issue is earnings quality, not the headline decline: mix from India and emerging markets is cushioning North American lenalidomide erosion, but that offset is exposed to acquired-brand contribution, launch execution and continued generic price pressure in Europe. Margin resilience is therefore not yet proof of a durable floor. Freight, inputs and higher planned R&D spend remain a near-term offset to mix benefits; management’s expectation of sequential gross-margin improvement should be tested against Q3/Q4 results, not capitalized as certain.

The most valuable catalysts are also binary or execution-dependent. Semaglutide needs successful validation and actual partner shipments before the expected restart supports revenue; production-scale execution remains the gating item. Abatacept carries a December FDA decision risk, with commercial uptake likely lagging approval while formularies and capacity ramp. Its prospective contribution is consequently a 2027+ option, not a near-term earnings backstop. The claimed CDMO expansion is attractive but requires evidence in signed work, revenue conversion and margins; trailing revenue alone does not establish the growth trajectory.

Working-capital expansion and cash paid on a legal claim reduce the comfort provided by net cash; track cash conversion and inventory, especially after the semaglutide scale-up disruption. Gilead’s expanded access collaboration and Takeda’s planned India vaccine launch are strategic distribution opportunities, but disclosed economics do not support assigning material near-term earnings to either. No valuation or consensus data are provided, so avoid a price-target call.

Key Decisions for Investors

• Keep Dr. Reddy’s on a catalyst watch rather than buying the earnings print. Consider a staged long only after validation is completed and commercial shipments are confirmed; reassess if the restart slips beyond the stated window or Q3/Q4 margins fail to hold around the current level despite mix support.
• Treat the Dec. 22 abatacept FDA date as event risk, not a base-case earnings estimate. Avoid adding exposure immediately ahead of the decision; a CRL or meaningful delay falsifies the near-term launch thesis, while approval still requires evidence of formulary access and early uptake.
• Monitor quarterly operating cash flow, inventory and receivables alongside reported margin. Rising working capital without corresponding semaglutide sales conversion would weaken the cash-quality thesis and warrant reducing exposure.
• Do not trade Gilead Sciences or Takeda on the collaboration announcements alone: wait for disclosed commercial terms, launch timing and evidence of revenue contribution. The article provides no basis to quantify impact on either company.